Key result
Oral anticoagulant therapy, including novel target-specific agents, carries ongoing risks of thromboembolic and bleeding complications that are expected to rise in the aging US population.
Population
Patients requiring oral anticoagulant therapy for conditions including nonvalvular atrial fibrillation…
Design
Review
Authors
Loading...
May warrant heightened OAC risk awareness in aging patients; leaves open impact of prediction tools on outcomes.
The prevalence of thromboembolic and bleeding complications during oral anticoagulant therapy is expected to rise in the US due to an aging population, highlighting the need for awareness and use of risk prediction tools.
Edith A. Nutescu (2013) conducted a review in Thromboembolism and bleeding. Oral anticoagulant therapy was evaluated. Oral anticoagulant therapy, including novel target-specific agents, carries ongoing risks of thromboembolic and bleeding complications that are expected to rise in the aging US population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: